IndustryCompany release

Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises

Prenetics Global Ltd (PRE) · Wed 18 Nov 2026

The Nasdaq-listed company reports positive Q3 adjusted free cash flow of $4.1 million, helped by borrowing, while raising planned customer-acquisition spend for its IM8 supplement brand.

Prenetics Global (NASDAQ: PRE) said in its Q3 2026 shareholder letter, published in November 2026, that Adjusted Free Cash Flow reached $4.1 million. The company noted that the figure was helped by $31.6 million of net drawdowns on its General Catalyst facility.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Prenetics Global Ltd ↗

Article written by VigiEye from the official source (Prenetics Global Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →